Rezultati pretraživanja
  1. prije 7 sati

    "Frankly, that APOC3 data kinda blew us away" Dr. Bruce Given, COO, 2/5/2020 First Quarter Conf. Call.

  2. prije 8 sati

    's Equity Research Report and $81 PT on challenging conventional thinking. Come see why it paved the way 3 months before all the others got there.

  3. Today reported promising interim results from ongoing Ph1/2a studies of our cardiometabolic candidates ARO-APOC3 being developed for severe & ARO-ANG3 being developed for & . Learn more:

  4. prije 8 sati

    Arrowhead reported interim clinical data on -based cardiometabolic candidates ARO-APOC3 (n=3) and ARO-ANG3 (n=22). Company expects initiation of pivotal studies this year. PR:

  5. prije 9 sati

    interim results for ARO-APOC3 and ARO-ANG3 - just WOW!!!

  6. prije 11 sati

    showed genetically validated targets are 2x as likely to be approved & is 10x as likely to advance as typical pharma. Data also applies to but likely worst case scenario, as ALNY was including its previous generations of delivery now abandoned for GalNAc ESC+

    Prikaži ovu nit
  7. prije 14 sati
  8. prije 18 sati

    Our assays are suitable for the assessment of to therapeutics - agents which are scoring approval.

  9. 4. velj

    Expecting an update on all programs tomorrow, but especially the 4 they now show advancing in Phase on the pipeline. APOC3 and ANG3 are now at PH2 while HSD and HIF2 are newly listed as phase 1 assets. Progressing as expected

  10. 4. velj

    Another very exciting paper from on . Thesis of culminating in to this interesting article about role of Argonaute slicing of maternal mRNAs! . Check it out for more details

  11. 4. velj

    Very excited to share our first preprint! Argonaute cleavage of maternal mRNAs in C. elegans embryos, check it out! Proud of and :) please send us your comments!

  12. 4. velj

    Tipbox picks its favorites from our 'Discovered: 20 years of breakthroughs' e-book. Which would you choose?

  13. 3. velj
    Odgovor korisniku/ci

    👨🏽‍🔬👩‍🔬📡💊🧪🔬maybe it’s time for and emojis as well :)

  14. 3. velj
  15. 31. sij

    The question though is would expend resources on this target and what are the chances for success? Might they discuss this during the call on Wednesday afternoon? As it is inhaled has significant potential against Cystic Fibrosis (CTA in next few months) COPD, Asthma

    Prikaži ovu nit
  16. 31. sij

    Strange that has been selling off during scare as they likely have as much capability to address as anyone who has announced treatment development. ARWR could potentially silence Spike protein using inhaled to inhibit replication.

    Prikaži ovu nit
  17. 31. sij

    Local press on Allstar team engineering bee gut bacteria to engage to defend against viruses and mites UT researchers take on honey bee decline

  18. 31. sij

    We’re pleased to announce that we’ve received a positive opinion from the EMA () Committee for Medicinal Products for Human Use () for our investigational therapeutic for the treatment of the acute hepatic .

  19. 30. sij

    If planning to take advantage of decline, next hour could be last opportunity before actual news starts to flow again. Beginning w/ CC tonight expect to learn plans for data release and PH2 start on AMG-890 for LP(a)

  20. 30. sij

    Plugging a 2019 article from beautifully explains RNA therapeutics

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.